SCHEMBL15935017

SCHEMBL15935017

Cc1ccn(-c2ccnc(C(F)(F)F)n2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
ATM Q13315 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MALT1 Q9UDY8 3/20 0.36
CYP17A1 P05093 1/20 0.34
NR1H2 P55055 2/20 0.33
NR1H3 Q13133 2/20 0.33
IDH1 O75874 2/20 0.33
IDH2 P48735 2/20 0.33
ACACB O00763 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTT P42858 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15935396 0.78 MAPT (0.61) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935020 0.76 CYP17A1 (0.36) MALT1CYP17A1NR1H2NR1H3IDH1
SCHEMBL19100786 0.76 MAPT (0.58) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935025 0.75 MAPT (0.53) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL28222796 0.74 KDM4E (0.44) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL15935402 0.74 MAPT (0.56) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935027 0.74 MAPT (0.51) MAPTRAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL15935408 0.73 HTT (0.42) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15935018 0.73 MAPT (0.54) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL15297136 0.72 ADRB1 (0.47) MAPTRAB9ANPC1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2934538-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2021-03-31 EP disclosed
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 MAPT 4751/4885RAB9A 556/4885NPC1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.